BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:6333-9. [PMID: 16670345 DOI: 10.4049/jimmunol.176.10.6333] [Cited by in Crossref: 398] [Cited by in F6Publishing: 378] [Article Influence: 24.9] [Reference Citation Analysis]
Number Citing Articles
1 Haq K, McElhaney JE. Ageing and respiratory infections: the airway of ageing. Immunol Lett 2014;162:323-8. [PMID: 24973652 DOI: 10.1016/j.imlet.2014.06.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
2 Roy JG, McElhaney JE, Verschoor CP. Reliable reference genes for the quantification of mRNA in human T-cells and PBMCs stimulated with live influenza virus. BMC Immunol 2020;21:4. [PMID: 32005148 DOI: 10.1186/s12865-020-0334-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, Rowland-Jones SL, McMichael AJ, Gilbert SC, Dong T. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS One 2013;8:e62778. [PMID: 23658773 DOI: 10.1371/journal.pone.0062778] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
4 Aspinall R, Lang PO. Vaccine responsiveness in the elderly: best practice for the clinic. Expert Review of Vaccines 2014;13:885-94. [DOI: 10.1586/14760584.2014.924403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. J Immunother Cancer 2021;9:e003428. [PMID: 34702753 DOI: 10.1136/jitc-2021-003428] [Reference Citation Analysis]
6 Li CK, Rappuoli R, Xu XN. Correlates of protection against influenza infection in humans--on the path to a universal vaccine? Curr Opin Immunol 2013;25:470-6. [PMID: 23948572 DOI: 10.1016/j.coi.2013.07.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
7 Epstein SL, Price GE. Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 2010;9:1325-41. [PMID: 21087110 DOI: 10.1586/erv.10.123] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
8 Ross K, Senapati S, Alley J, Darling R, Goodman J, Jefferson M, Uz M, Guo B, Yoon K, Verhoeven D, Kohut M, Mallapragada S, Wannemuehler M, Narasimhan B. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice. Biomater Sci 2019;7:809-21. [DOI: 10.1039/c8bm01443d] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
9 Chauvat A, Benhamouda N, Loison E, Gougeon ML, Gey A, Levionnois E, Ravel P, Abitbol V, Roncelin S, Marcheteau E, Quintin-Colonna F, Fridman WH, Launay O, Tartour E. Pitfalls in anti-influenza T cell detection by Elispot using thimerosal containing pandemic H1N1 vaccine as antigen. J Immunol Methods 2012;378:81-7. [PMID: 22366633 DOI: 10.1016/j.jim.2012.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
10 Tan AC, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC. The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 2013;91:96-104. [PMID: 23146941 DOI: 10.1038/icb.2012.54] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
11 Vogel AJ, Brown DM. Single-Dose CpG Immunization Protects Against a Heterosubtypic Challenge and Generates Antigen-Specific Memory T Cells. Front Immunol 2015;6:327. [PMID: 26161083 DOI: 10.3389/fimmu.2015.00327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
12 Siebert JC, Walker EB. Monitoring cytokine profiles during immunotherapy. Immunotherapy 2010;2:799-816. [PMID: 21091113 DOI: 10.2217/imt.10.76] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
13 Yaqoob P. Ageing, immunity and influenza: a role for probiotics? Proc Nutr Soc 2014;73:309-17. [PMID: 24300282 DOI: 10.1017/S0029665113003777] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
14 Gonçalves E, Combadière B. Prédire la réponse à la vaccination contre la grippe: Vers l’identification d’une signature moléculaire précoce. Med Sci (Paris) 2020;36:31-7. [DOI: 10.1051/medsci/2019266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 van Essen GA, Beran J, Devaster JM, Durand C, Duval X, Esen M, Falsey AR, Feldman G, Gervais P, Innis BL, Kovac M, Launay O, Leroux-Roels G, McElhaney JE, McNeil S, Oujaa M, Richardus JH, Ruiz-Palacios G, Osborne RH, Oostvogels L. Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza Other Respir Viruses 2014;8:452-62. [PMID: 24702710 DOI: 10.1111/irv.12245] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lohia N, Baranwal M. Conserved peptides containing overlapping CD4+ and CD8+ T-cell epitopes in the H1N1 influenza virus: an immunoinformatics approach. Viral Immunol 2014;27:225-34. [PMID: 24821387 DOI: 10.1089/vim.2013.0135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
17 Eaton SM, Maue AC, Swain SL, Haynes L. Bone marrow precursor cells from aged mice generate CD4 T cells that function well in primary and memory responses. J Immunol 2008;181:4825-31. [PMID: 18802086 DOI: 10.4049/jimmunol.181.7.4825] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
18 Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol. 2009;21:440-445. [PMID: 19535233 DOI: 10.1016/j.coi.2009.05.012] [Cited by in Crossref: 154] [Cited by in F6Publishing: 141] [Article Influence: 11.8] [Reference Citation Analysis]
19 Smetana J, Chlibek R, Shaw J, Splino M, Prymula R. Influenza vaccination in the elderly. Hum Vaccin Immunother 2018;14:540-9. [PMID: 28708957 DOI: 10.1080/21645515.2017.1343226] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
20 Pascoe AR, Fiatarone Singh MA, Edwards KM. The effects of exercise on vaccination responses: a review of chronic and acute exercise interventions in humans. Brain Behav Immun. 2014;39:33-41. [PMID: 24126151 DOI: 10.1016/j.bbi.2013.10.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 6.7] [Reference Citation Analysis]
21 Sabarth N, Savidis-Dacho H, Schwendinger MG, Brühl P, Portsmouth D, Crowe BA, Kistner O, Barrett PN, Kreil TR, Howard MK. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination. Vaccine 2012;30:5533-40. [PMID: 22749797 DOI: 10.1016/j.vaccine.2012.06.043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
22 Amorij JP, Hinrichs WLj, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010;10:699-711. [PMID: 20883966 DOI: 10.1016/S1473-3099(10)70157-2] [Cited by in Crossref: 85] [Cited by in F6Publishing: 32] [Article Influence: 7.1] [Reference Citation Analysis]
23 Mehta P, Sanchez E, Moraitis E, Longley N, Lendrem DW, Giles IP, Chambers RC, Ciurtin C, Isaacs JD. Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. Lancet Rheumatol 2021;3:e9-e10. [PMID: 33521669 DOI: 10.1016/S2665-9913(20)30392-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kang CK, Kim HR, Song KH, Keam B, Choi SJ, Choe PG, Kim ES, Kim NJ, Kim YJ, Park WB, Kim HB, Oh MD. Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors. J Infect Dis 2020;222:1902-9. [PMID: 32479600 DOI: 10.1093/infdis/jiaa291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
25 Liu H, Bungener L, ter Veer W, Coller B, Wilschut J, Huckriede A. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine 2011;29:2037-43. [DOI: 10.1016/j.vaccine.2011.01.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
26 Zhou X, McElhaney JE. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 2011;29:2169-77. [PMID: 21353149 DOI: 10.1016/j.vaccine.2010.12.029] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
27 Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 2012;86:6792-6803. [PMID: 22491469 DOI: 10.1128/JVI.07172-11] [Cited by in Crossref: 146] [Cited by in F6Publishing: 113] [Article Influence: 14.6] [Reference Citation Analysis]
28 Brown LE, Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009;87:300-8. [PMID: 19308073 DOI: 10.1038/icb.2009.16] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 6.0] [Reference Citation Analysis]
29 Oviedo-Orta E, Li CK, Rappuoli R. Perspectives on vaccine development for the elderly. Curr Opin Immunol 2013;25:529-34. [PMID: 24001371 DOI: 10.1016/j.coi.2013.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
30 Héquet D, Pascual M, Lartey S, Pathirana RD, Bredholt G, Hoschler K, Hullin R, Meylan P, Cox RJ, Manuel O. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies. Vaccine 2016;34:3576-83. [PMID: 27219339 DOI: 10.1016/j.vaccine.2016.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
31 Schotsaert M, Ibañez LI, Fiers W, Saelens X. Controlling influenza by cytotoxic T-cells: calling for help from destroyers. J Biomed Biotechnol 2010;2010:863985. [PMID: 20508820 DOI: 10.1155/2010/863985] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
32 Keilich SR, Bartley JM, Haynes L. Diminished immune responses with aging predispose older adults to common and uncommon influenza complications. Cell Immunol 2019;345:103992. [PMID: 31627841 DOI: 10.1016/j.cellimm.2019.103992] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
33 Jeong YJ, Kim YJ, Kim SH, Yoo J, Lee J, Lee S, Il Kim S. Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center. Journal of Infection and Public Health 2022. [DOI: 10.1016/j.jiph.2022.02.005] [Reference Citation Analysis]
34 Moss AJ, Gaughran FP, Karasu A, Gilbert AS, Mann AJ, Gelder CM, Oxford JS, Stephens HA, Lambkin-Williams R. Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination. PLoS One 2013;8:e71376. [PMID: 23951151 DOI: 10.1371/journal.pone.0071376] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
35 Yao X, Hamilton RG, Weng NP, Xue QL, Bream JH, Li H, Tian J, Yeh SH, Resnick B, Xu X, Walston J, Fried LP, Leng SX. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine 2011;29:5015-21. [PMID: 21565245 DOI: 10.1016/j.vaccine.2011.04.077] [Cited by in Crossref: 105] [Cited by in F6Publishing: 81] [Article Influence: 9.5] [Reference Citation Analysis]
36 Yusibov V, Kushnir N, Streatfield SJ. Advances and challenges in the development and production of effective plant-based influenza vaccines. Expert Rev Vaccines 2015;14:519-35. [PMID: 25487788 DOI: 10.1586/14760584.2015.989988] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
37 Barnett JB, Hamer DH, Meydani SN. Low zinc status: a new risk factor for pneumonia in the elderly? Nutr Rev 2010;68:30-7. [PMID: 20041998 DOI: 10.1111/j.1753-4887.2009.00253.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
38 Pellegrino P, Carnovale C, Borsadoli C, Danini T, Speziali A, Perrone V, Antoniazzi S, Pozzi M, Clementi E, Radice S. Two cases of hallucination in elderly patients due to a probable interaction between flu immunization and tramadol. Eur J Clin Pharmacol 2013;69:1615-6. [DOI: 10.1007/s00228-013-1517-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
39 Neimert-andersson T, Binnmyr J, Enoksson M, Langebäck J, Zettergren L, Hällgren A, Franzén H, Lind Enoksson S, Lafolie P, Lindberg A, Al-tawil N, Andersson M, Singer P, Grönlund H, Gafvelin G. Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial. Vaccine 2014;32:5967-74. [DOI: 10.1016/j.vaccine.2014.08.057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
40 Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: Implications for COVID-19 vaccines. J Med Virol 2021. [PMID: 34845730 DOI: 10.1002/jmv.27485] [Reference Citation Analysis]
41 Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008;197:490-502. [PMID: 18275271 DOI: 10.1086/524146] [Cited by in Crossref: 115] [Cited by in F6Publishing: 108] [Article Influence: 8.2] [Reference Citation Analysis]
42 Babon JA, Cruz J, Orphin L, Pazoles P, Co MD, Ennis FA, Terajima M. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum Immunol 2009;70:711-21. [PMID: 19524006 DOI: 10.1016/j.humimm.2009.06.004] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
43 Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, De Gregorio E, Mason PW, Ulmer JB, Geall AJ, Bertholet S. Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin. J Virol 2016;90:332-44. [PMID: 26468547 DOI: 10.1128/JVI.01786-15] [Cited by in Crossref: 74] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
44 Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirirotchanakul S, Dhitavat J, Thirapakpoomanunt S, Chokevivat V, Wibulpolprasert S. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. Vaccine 2013;31:1503-9. [PMID: 23318149 DOI: 10.1016/j.vaccine.2012.12.082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
45 Frasca D, Blomberg BB. B cell function and influenza vaccine responses in healthy aging and disease. Curr Opin Immunol 2014;29:112-8. [PMID: 24934648 DOI: 10.1016/j.coi.2014.05.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
46 Lanzer KG, Johnson LL, Woodland DL, Blackman MA. Impact of ageing on the response and repertoire of influenza virus-specific CD4 T cells. Immun Ageing 2014;11:9. [PMID: 24999367 DOI: 10.1186/1742-4933-11-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
47 Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-9. [PMID: 18558875 DOI: 10.1086/589862] [Cited by in Crossref: 517] [Cited by in F6Publishing: 487] [Article Influence: 36.9] [Reference Citation Analysis]
48 Boraschi D, Italiani P. Immunosenescence and vaccine failure in the elderly: Strategies for improving response. Immunology Letters 2014;162:346-53. [DOI: 10.1016/j.imlet.2014.06.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
49 Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev Vaccines 2009;8:1205-20. [PMID: 19722894 DOI: 10.1586/erv.09.82] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
50 Dulek DE, de St Maurice A, Halasa NB. Vaccines in pediatric transplant recipients-Past, present, and future. Pediatr Transplant 2018;22:e13282. [PMID: 30207024 DOI: 10.1111/petr.13282] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Grebenciucova E, Berger JR. Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis. Curr Neurol Neurosci Rep 2017;17:61. [PMID: 28669032 DOI: 10.1007/s11910-017-0771-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
52 Castilla J, Navascués A, Fernández-Alonso M, Reina G, Pozo F, Casado I, Guevara M, Martínez-Baz I, Barricarte A, Ezpeleta C; Primary Health Care Sentinel Network., Network for Influenza Surveillance in Hospitals of Navarra. Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons. Vaccine 2016;34:1350-7. [PMID: 26854911 DOI: 10.1016/j.vaccine.2016.01.054] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
53 Stephenson I, Hayden F, Osterhaus A, Howard W, Pervikov Y, Palkonyay L, Kieny MP. Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. Vaccine 2010;28:3875-82. [PMID: 20398616 DOI: 10.1016/j.vaccine.2010.03.074] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
54 Duvvuri VR, Heffernan JM, Moghadas SM, Duvvuri B, Guo H, Fisman DN, Wu J, Wu GE. The role of cellular immunity in influenza H1N1 population dynamics. BMC Infect Dis 2012;12:329. [PMID: 23192104 DOI: 10.1186/1471-2334-12-329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Keynan Y, Card CM, Ball BT, Li Y, Plummer FA, Fowke KR. Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains. Clin Microbiol Infect 2010;16:1179-86. [PMID: 20670292 DOI: 10.1111/j.1469-0691.2010.03142.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
56 Bolton KJ, McCaw JM, Brown L, Jackson D, Kedzierska K, McVernon J. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control. PLoS One 2015;10:e0120138. [PMID: 25811654 DOI: 10.1371/journal.pone.0120138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
57 van den Berg SPH, Lanfermeijer J, Jacobi RHJ, Hendriks M, Vos M, van Schuijlenburg R, Nanlohy NM, Borghans JAM, van Beek J, van Baarle D, de Wit J. Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection. Front Immunol 2021;12:663664. [PMID: 34025665 DOI: 10.3389/fimmu.2021.663664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine 2008;26 Suppl 4:D5-9. [PMID: 18602728 DOI: 10.1016/j.vaccine.2008.05.076] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 5.5] [Reference Citation Analysis]
59 Xie D, McElhaney JE. Lower GrB+ CD62Lhigh CD8 TCM effector lymphocyte response to influenza virus in older adults is associated with increased CD28null CD8 T lymphocytes. Mech Ageing Dev 2007;128:392-400. [PMID: 17570460 DOI: 10.1016/j.mad.2007.05.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
60 Singh M, Kazzaz J, Ugozzoli M, Baudner B, Pizza M, Giuliani M, Hawkins LD, Otten G, O'Hagan DT. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Hum Vaccin Immunother 2012;8:486-90. [PMID: 22832252 DOI: 10.4161/hv.19229] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
61 Marriott AC, Dennis M, Kane JA, Gooch KE, Hatch G, Sharpe S, Prevosto C, Leeming G, Zekeng EG, Staples KJ, Hall G, Ryan KA, Bate S, Moyo N, Whittaker CJ, Hallis B, Silman NJ, Lalvani A, Wilkinson TM, Hiscox JA, Stewart JP, Carroll MW. Influenza A Virus Challenge Models in Cynomolgus Macaques Using the Authentic Inhaled Aerosol and Intra-Nasal Routes of Infection. PLoS One 2016;11:e0157887. [PMID: 27311020 DOI: 10.1371/journal.pone.0157887] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
62 Woods JA, Keylock KT, Lowder T, Vieira VJ, Zelkovich W, Dumich S, Colantuano K, Lyons K, Leifheit K, Cook M. Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial. J Am Geriatr Soc. 2009;57:2183-2191. [PMID: 20121985 DOI: 10.1111/j.1532-5415.2009.02563.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 66] [Article Influence: 7.2] [Reference Citation Analysis]
63 Bresee JS, Fry AM, Sambhara S, Cox NJ. Inactivated Influenza Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 456-488.e21. [DOI: 10.1016/b978-0-323-35761-6.00031-6] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
64 Bao W, Li Y, Wang T, Li X, He J, Wang Y, Wen F, Chen J. Effects of influenza vaccination on clinical outcomes of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Ageing Res Rev 2021;68:101337. [PMID: 33813014 DOI: 10.1016/j.arr.2021.101337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Nikolich-Žugich J, Li G, Uhrlaub JL, Renkema KR, Smithey MJ. Age-related changes in CD8 T cell homeostasis and immunity to infection. Semin Immunol 2012;24:356-64. [PMID: 22554418 DOI: 10.1016/j.smim.2012.04.009] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 8.0] [Reference Citation Analysis]
66 Couch RB, Bayas JM, Caso C, Mbawuike IN, López CN, Claeys C, El Idrissi M, Hervé C, Laupèze B, Oostvogels L, Moris P. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infect Dis 2014;14:425. [PMID: 25078387 DOI: 10.1186/1471-2334-14-425] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
67 Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, Mompoint F, Vedvick TS, Bertholet S, Coler RN, Reed SG. Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009;27:5956-63. [DOI: 10.1016/j.vaccine.2009.07.081] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 6.3] [Reference Citation Analysis]
68 McElhaney JE, Gentleman B. Cell-Mediated Immune Response to Influenza Using Ex Vivo Stimulation and Assays of Cytokine and Granzyme B Responses. Methods Mol Biol 2015;1343:121-41. [PMID: 26420714 DOI: 10.1007/978-1-4939-2963-4_11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
69 Wang SM, Tsai MH, Lei HY, Wang JR, Liu CC. The regulatory T cells in anti-influenza antibody response post influenza vaccination. Hum Vaccin Immunother 2012;8:1243-9. [PMID: 22894960 DOI: 10.4161/hv.21117] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
70 Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol 2020;348:103998. [PMID: 31733824 DOI: 10.1016/j.cellimm.2019.103998] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
71 Gemmill I, Young K. Summary of the NACI literature review on the comparative effectiveness of subunit and split virus inactivated influenza vaccines in older adults. Can Commun Dis Rep 2018;44:129-33. [PMID: 31015805 DOI: 10.14745/ccdr.v44i06a02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Iorio AM, Bistoni O, Galdiero M, Lepri E, Camilloni B, Russano AM, Neri M, Basileo M, Spinozzi F. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Vaccine 2012;30:1617-23. [PMID: 22245606 DOI: 10.1016/j.vaccine.2011.12.107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
73 Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015;33:246-51. [PMID: 24962752 DOI: 10.1016/j.vaccine.2014.06.052] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 10.6] [Reference Citation Analysis]
74 Goswami M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, Cheung F, Kotliarov Y, Chen J, Shi R, Zhou H, Golding H, Manischewitz J, King L, Kunz LM, Noonan K, Borrello IM, Smith BD, Hourigan CS. Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. J Transl Med 2017;15:155. [PMID: 28693586 DOI: 10.1186/s12967-017-1252-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
75 Vassilieva EV, Li S, Korniychuk H, Taylor DM, Wang S, Prausnitz MR, Compans RW. cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model. Front Immunol 2020;11:583251. [PMID: 33603732 DOI: 10.3389/fimmu.2020.583251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, Renzoni A, Fabbri P, Ferrera A, Parodi A, Bruzzone B, Gabutti G, Podda A, Del Giudice G, Fragapane E, Indiveri F, Crovari P, Gasparini R. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008;15:253-9. [PMID: 18003811 DOI: 10.1128/CVI.00316-07] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
77 Xie D. Fluorescent dye labeled influenza virus mainly infects innate immune cells and activated lymphocytes and can be used in cell-mediated immune response assay. J Immunol Methods 2009;343:42-8. [PMID: 19330946 DOI: 10.1016/j.jim.2009.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
78 Hung IF, Zhang AJ, To KK, Chan JF, Li C, Zhu HS, Li P, Li C, Chan TC, Cheng VC, Chan KH, Yuen KY. Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. Clin Infect Dis 2014;59:1246-55. [PMID: 25048848 DOI: 10.1093/cid/ciu582] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
79 Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Review of Vaccines 2014;8:483-92. [DOI: 10.1586/erv.09.5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
80 Reikie BA, Smolen KK, Fortuno ES 3rd, Loeffler DI, Cai B, Blimkie D, Kollmann TR. A single immunization near birth elicits immediate and lifelong protective immunity. Vaccine 2010;29:83-90. [PMID: 21034825 DOI: 10.1016/j.vaccine.2010.10.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
81 Brown DM, Kamperschroer C, Dilzer AM, Roberts DM, Swain SL. IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell Immunol 2009;257:69-79. [PMID: 19338979 DOI: 10.1016/j.cellimm.2009.03.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
82 Alexander J, Bilsel P, del Guercio MF, Stewart S, Marinkovic-Petrovic A, Southwood S, Crimi C, Vang L, Walker L, Ishioka G, Chitnis V, Sette A, Assarsson E, Hannaman D, Botten J, Newman MJ. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 2010;28:664-72. [PMID: 19895924 DOI: 10.1016/j.vaccine.2009.10.103] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
83 McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, Barry MB, Kleppinger A, Wang Y, Bleackley RC. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009;27:2418-25. [PMID: 19368783 DOI: 10.1016/j.vaccine.2009.01.136] [Cited by in F6Publishing: 128] [Reference Citation Analysis]
84 Dembinski JL, Hungnes O, Hauge AG, Kristoffersen AC, Haneberg B, Mjaaland S. Hydrogen peroxide inactivation of influenza virus preserves antigenic structure and immunogenicity. J Virol Methods 2014;207:232-7. [PMID: 25025814 DOI: 10.1016/j.jviromet.2014.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
85 Angel JB, Cooper CL, Clinch J, Young CD, Chenier A, Parato KG, Lautru M, Davis H, Cameron DW. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J Immune Based Ther Vaccines 2008;6:4. [PMID: 18700037 DOI: 10.1186/1476-8518-6-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
86 Pellegrino P, Perrotta C, Clementi E, Radice S. Vaccine–Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms. Drug Saf 2015;38:781-7. [DOI: 10.1007/s40264-015-0330-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
87 Esposito S, Principi N. Clinical trial research in focus: factors that hamper the development and evaluation of influenza vaccines. Lancet Respir Med 2017;5:164-6. [PMID: 28266323 DOI: 10.1016/S2213-2600(17)30058-9] [Reference Citation Analysis]
88 Fulop T, Pawelec G, Castle S, Loeb M. Immunosenescence and vaccination in nursing home residents. Clin Infect Dis 2009;48:443-8. [PMID: 19140756 DOI: 10.1086/596475] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
89 Elliott STC, Keaton AA, Chu JD, Reed CC, Garman B, Patel A, Yan J, Broderick KE, Weiner DB. A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses. Hum Gene Ther 2018;29:1044-55. [PMID: 30062926 DOI: 10.1089/hum.2018.102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
90 Yan AW, Cao P, Heffernan JM, McVernon J, Quinn KM, La Gruta NL, Laurie KL, McCaw JM. Modelling cross-reactivity and memory in the cellular adaptive immune response to influenza infection in the host. J Theor Biol 2017;413:34-49. [PMID: 27856216 DOI: 10.1016/j.jtbi.2016.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
91 Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, Wilson PC, Ennis FA. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 2011;85:13463-7. [PMID: 21994454 DOI: 10.1128/JVI.05193-11] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
92 Wong-Chew RM, Frías MN, García-León ML, Arriaga-Pizano L, Sanson AM, Lopez-Macías C, Isibasi A, Santos-Preciado JI. Humoral and cellular immune responses to influenza vaccination in children with cancer receiving chemotherapy. Oncol Lett 2012;4:329-33. [PMID: 22844379 DOI: 10.3892/ol.2012.721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
93 Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, Krause G, Buda S, Haas W. Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS One 2011;6:e21340. [PMID: 21701598 DOI: 10.1371/journal.pone.0021340] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
94 Duvvuri VR, Duvvuri B, Alice C, Wu GE, Gubbay JB, Wu J. Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses. PLoS One 2014;9:e91273. [PMID: 24609014 DOI: 10.1371/journal.pone.0091273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
95 Grødeland G, Fossum E, Bogen B. Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines. Front Immunol 2015;6:367. [PMID: 26257735 DOI: 10.3389/fimmu.2015.00367] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
96 Verschoor CP, Andrew MK, Loeb M, Pawelec G, Haynes L, Kuchel GA, McElhaney JE. Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults. Vaccines (Basel) 2021;9:25. [PMID: 33430191 DOI: 10.3390/vaccines9010025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Johns MC, Eick AA, Blazes DL, Lee SE, Perdue CL, Lipnick R, Vest KG, Russell KL, DeFraites RF, Sanchez JL. Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. PLoS One 2010;5:e10722. [PMID: 20502705 DOI: 10.1371/journal.pone.0010722] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
98 Madan A, Ferguson M, Rheault P, Seiden D, Toma A, Friel D, Soni J, Li P, Innis BL, Schuind A. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial. Vaccine 2017;35:1865-72. [PMID: 28302407 DOI: 10.1016/j.vaccine.2017.02.057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
99 Adams AA, Sturgill TL, Breathnach CC, Chambers TM, Siger L, Minke JM, Horohov DW. Humoral and cell-mediated immune responses of old horses following recombinant canarypox virus vaccination and subsequent challenge infection. Veterinary Immunology and Immunopathology 2011;139:128-40. [DOI: 10.1016/j.vetimm.2010.09.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
100 Patel MM, York IA, Monto AS, Thompson MG, Fry AM. Immune-mediated attenuation of influenza illness after infection: opportunities and challenges. The Lancet Microbe 2021;2:e715-25. [DOI: 10.1016/s2666-5247(21)00180-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Gorenjak V, Vance DR, Petrelis AM, Stathopoulou MG, Dadé S, El Shamieh S, Murray H, Masson C, Lamont J, Fitzgerald P, Visvikis-Siest S. Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population. PLoS One 2019;14:e0220902. [PMID: 31419243 DOI: 10.1371/journal.pone.0220902] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
102 Juno J, Fowke KR, Keynan Y. Immunogenetic factors associated with severe respiratory illness caused by zoonotic H1N1 and H5N1 influenza viruses. Clin Dev Immunol 2012;2012:797180. [PMID: 22110538 DOI: 10.1155/2012/797180] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
103 Roose K, Schotsaert M, Bakkouri KE, Schepens B, Fiers W, Saelens X. Cutting Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines. In: von Gabain A, Klade C, editors. Development of Novel Vaccines. Vienna: Springer; 2012. pp. 205-32. [DOI: 10.1007/978-3-7091-0709-6_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
104 McElhaney JE, Kuchel GA, Zhou X, Swain SL, Haynes L. T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines. Front Immunol 2016;7:41. [PMID: 26941738 DOI: 10.3389/fimmu.2016.00041] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 13.2] [Reference Citation Analysis]
105 Amoah S, Mishina M, Praphasiri P, Cao W, Kim JH, Liepkalns JS, Guo Z, Carney PJ, Chang JC, Fernandez S, Garg S, Beacham L, Holtz TH, Curlin ME, Dawood F, Olsen SJ, Gangappa S, Stevens J, Sambhara S. Standard-Dose Intradermal Influenza Vaccine Elicits Cellular Immune Responses Similar to Those of Intramuscular Vaccine in Men With and Those Without HIV Infection. J Infect Dis 2019;220:743-51. [PMID: 31045222 DOI: 10.1093/infdis/jiz205] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Long BR, Michaelsson J, Loo CP, Ballan WM, Vu BA, Hecht FM, Lanier LL, Chapman JM, Nixon DF. Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol 2008;15:120-30. [PMID: 18003818 DOI: 10.1128/CVI.00357-07] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
107 Scaglione A, Opp S, Hurtado A, Lin Z, Pampeno C, Noval MG, Thannickal SA, Stapleford KA, Meruelo D. Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity. bioRxiv 2021:2021. [PMID: 34075383 DOI: 10.1101/2021.05.28.446009] [Reference Citation Analysis]
108 Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008;26:5393-9. [DOI: 10.1016/j.vaccine.2008.07.084] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 7.3] [Reference Citation Analysis]
109 Engelmann F, Rivera A, Park B, Messerle-Forbes M, Jensen JT, Messaoudi I. Impact of Estrogen Therapy on Lymphocyte Homeostasis and the Response to Seasonal Influenza Vaccine in Post-Menopausal Women. PLoS One 2016;11:e0149045. [PMID: 26859566 DOI: 10.1371/journal.pone.0149045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
110 Murdaca G, Orsi A, Spanò F, Puppo F, Durando P, Icardi G, Ansaldi F. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. Autoimmunity Reviews 2014;13:75-84. [DOI: 10.1016/j.autrev.2013.07.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
111 Loison E, Poirier-Beaudouin B, Seffer V, Paoletti A, Abitbol V, Tartour E, Launay O, Gougeon ML. Suppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells. PLoS One 2014;9:e92705. [PMID: 24690681 DOI: 10.1371/journal.pone.0092705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
112 Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines 2012;11:985-94. [PMID: 23002979 DOI: 10.1586/erv.12.61] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 10.1] [Reference Citation Analysis]
113 Canaday DH, Gravenstein S. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. Clin Infect Dis 2021;72:513-4. [PMID: 33527123 DOI: 10.1093/cid/ciaa726] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007;26:119-27. [DOI: 10.1016/j.vaccine.2007.10.051] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
115 Grant RW, Mariani RA, Vieira VJ, Fleshner M, Smith TP, Keylock KT, Lowder TW, McAuley E, Hu L, Chapman-Novakofski K. Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults. Brain Behav Immun. 2008;22:923-932. [PMID: 18295445 DOI: 10.1016/j.bbi.2008.01.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
116 Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, Peters B. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009;106:20365-70. [PMID: 19918065 DOI: 10.1073/pnas.0911580106] [Cited by in Crossref: 245] [Cited by in F6Publishing: 229] [Article Influence: 18.8] [Reference Citation Analysis]
117 Krammer F, Cox RJ. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Review of Vaccines 2014;12:1369-72. [DOI: 10.1586/14760584.2013.850036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
118 Lefebvre JS, Haynes L. Vaccine strategies to enhance immune responses in the aged. Curr Opin Immunol 2013;25:523-8. [PMID: 23764092 DOI: 10.1016/j.coi.2013.05.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
119 Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055-65. [PMID: 20463105 DOI: 10.1128/CVI.00131-10] [Cited by in Crossref: 900] [Cited by in F6Publishing: 509] [Article Influence: 75.0] [Reference Citation Analysis]
120 Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, Sarbagil-Maman H, Paran D, Caspi D, Elkayam O. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011;29:1643-8. [PMID: 21211590 DOI: 10.1016/j.vaccine.2010.12.072] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
121 Merani S, Pawelec G, Kuchel GA, McElhaney JE. Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. Front Immunol 2017;8:784. [PMID: 28769922 DOI: 10.3389/fimmu.2017.00784] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
122 Lee JB, Oelke M, Ramachandra L, Canaday DH, Schneck JP. Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immun Ageing 2011;8:6. [PMID: 21846352 DOI: 10.1186/1742-4933-8-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
123 van Assen S, Bijl M. Immunization of patients with autoimmune inflammatory rheumatic diseases (the EULAR recommendations). Lupus 2012;21:162-7. [DOI: 10.1177/0961203311429555] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
124 Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv 2021;5:2624-43. [PMID: 34152403 DOI: 10.1182/bloodadvances.2021004629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
125 Jonges M, Liu WM, van der Vries E, Jacobi R, Pronk I, Boog C, Koopmans M, Meijer A, Soethout E. Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. J Clin Microbiol 2010;48:928-40. [PMID: 20089763 DOI: 10.1128/JCM.02045-09] [Cited by in Crossref: 62] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
126 Song H, Wittman V, Byers A, Tapia T, Zhou B, Warren W, Heaton P, Connolly K. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 2010;28:5524-32. [PMID: 20600506 DOI: 10.1016/j.vaccine.2010.06.044] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
127 Landry N, Pillet S, Favre D, Poulin JF, Trépanier S, Yassine-Diab B, Ward BJ. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol 2014;154:164-77. [PMID: 25128897 DOI: 10.1016/j.clim.2014.08.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
128 Treanor JJ. Influenza Viruses, Including Avian Influenza and Swine Influenza. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2265-88. [DOI: 10.1016/b978-0-443-06839-3.00165-x] [Cited by in Crossref: 16] [Article Influence: 1.3] [Reference Citation Analysis]
129 Wu KW, Chien CY, Li SW, King CC, Chang CH. Highly conserved influenza A virus epitope sequences as candidates of H3N2 flu vaccine targets. Genomics 2012;100:102-9. [PMID: 22698979 DOI: 10.1016/j.ygeno.2012.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
130 Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, Sebastian R, Chong M, Tam T, De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007;25:2842-51. [PMID: 17081662 DOI: 10.1016/j.vaccine.2006.10.002] [Cited by in Crossref: 128] [Cited by in F6Publishing: 133] [Article Influence: 8.0] [Reference Citation Analysis]
131 Terajima M, Cruz J, Leporati AM, Orphin L, Babon JA, Co MD, Pazoles P, Jameson J, Ennis FA. Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients. J Virol 2008;82:9283-7. [PMID: 18614638 DOI: 10.1128/JVI.01047-08] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
132 Waterer G, Wunderink R. Respiratory infections: a current and future threat. Respirology 2009;14:651-5. [PMID: 19659646 DOI: 10.1111/j.1440-1843.2009.01554.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
133 Neidich SD, Green WD, Rebeles J, Karlsson EA, Schultz-Cherry S, Noah TL, Chakladar S, Hudgens MG, Weir SS, Beck MA. Increased risk of influenza among vaccinated adults who are obese. Int J Obes (Lond) 2017;41:1324-30. [PMID: 28584297 DOI: 10.1038/ijo.2017.131] [Cited by in Crossref: 120] [Cited by in F6Publishing: 104] [Article Influence: 24.0] [Reference Citation Analysis]
134 Yang Y, Verkuilen J, Rosengren KS, Mariani RA, Reed M, Grubisich SA, Woods JA. Effects of a Taiji and Qigong Intervention on the Antibody Response to Influenza Vaccine in Older Adults. Am J Chin Med 2012;35:597-607. [DOI: 10.1142/s0192415x07005090] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
135 Connolly R, Denton MD, Humphreys H, McLoughlin RM. Would hemodialysis patients benefit from a Staphylococcus aureus vaccine? Kidney Int 2019;95:518-25. [PMID: 30691691 DOI: 10.1016/j.kint.2018.10.023] [Reference Citation Analysis]
136 van Assen S, de Haan A, Holvast A, Horst G, Gorter L, Westra J, Kallenberg CG, Telgt DS, Palache AM, Giezeman KM, Bijl M. Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency. Clinical Immunology 2011;141:161-8. [DOI: 10.1016/j.clim.2011.07.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
137 Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, Burdin N, Poidinger M, Tambyah PA, Bosco N, Visan L, Ng TP, Larbi A. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure. Front Immunol 2018;9:2465. [PMID: 30405641 DOI: 10.3389/fimmu.2018.02465] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
138 Hata A, Mano C, Nakamura Y, Nishida H, Kumakura A, Mizumoto H, Yoshioka T, Yoshida Y, Shiota M, Hata D, Takahashi K. Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan. Human Vaccines & Immunotherapeutics 2014;8:587-91. [DOI: 10.4161/hv.19296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, Hawkins LD, Wack A, O’hagan DT. MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020). Pharm Res 2009;26:1477-85. [DOI: 10.1007/s11095-009-9859-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
140 Wong JP, Christopher ME, Viswanathan S, Schnell G, Dai X, Van Loon D, Stephen ER. Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. Expert Review of Respiratory Medicine 2014;4:171-7. [DOI: 10.1586/ers.10.15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
141 Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008;3:e1401. [PMID: 18167560 DOI: 10.1371/journal.pone.0001401] [Cited by in Crossref: 128] [Cited by in F6Publishing: 127] [Article Influence: 9.1] [Reference Citation Analysis]
142 Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, Gilbert SC. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 2012;7:e48322. [PMID: 23118984 DOI: 10.1371/journal.pone.0048322] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 8.8] [Reference Citation Analysis]
143 Lang PO, Aspinall R. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules? Expert Rev Vaccines 2012;11:167-76. [PMID: 22309666 DOI: 10.1586/erv.11.187] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
144 Kirsteina A, Akopjana I, Bogans J, Lieknina I, Jansons J, Skrastina D, Kazaka T, Tars K, Isakova-Sivak I, Mezhenskaya D, Kotomina T, Matyushenko V, Rudenko L, Kazaks A. Construction and Immunogenicity of a Novel Multivalent Vaccine Prototype Based on Conserved Influenza Virus Antigens. Vaccines (Basel) 2020;8:E197. [PMID: 32344753 DOI: 10.3390/vaccines8020197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
145 Skibinski DAG, Jones LA, Zhu YO, Xue LW, Au B, Lee B, Naim ANM, Lee A, Kaliaperumal N, Low JGH, Lee LS, Poidinger M, Saudan P, Bachmann M, Ooi EE, Hanson BJ, Novotny-Diermayr V, Matter A, Fairhurst AM, Hibberd ML, Connolly JE. Induction of Human T-cell and Cytokine Responses Following Vaccination with a Novel Influenza Vaccine. Sci Rep 2018;8:18007. [PMID: 30573748 DOI: 10.1038/s41598-018-36703-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
146 Tang YC, Thoman M, Linton P, Deisseroth A. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged. Cancer Immunol Immunother 2009;58:1949-57. [DOI: 10.1007/s00262-009-0718-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
147 Ryu JI, Park SA, Wui SR, Ko A, Han JE, Choi JA, Song MK, Kim KS, Cho YJ, Lee NG. A De-O-acylated Lipooligosaccharide-Based Adjuvant System Promotes Antibody and Th1-Type Immune Responses to H1N1 Pandemic Influenza Vaccine in Mice. Biomed Res Int 2016;2016:3713656. [PMID: 27891512 DOI: 10.1155/2016/3713656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
148 Zastrow A, Schnitzler P, Eckerle I, Herzog W, Friederich HC. Immunogenicity and safety of H1N1 vaccination in anorexia nervosa--results from a pilot study. Int J Eat Disord 2012;45:146-9. [PMID: 22170028 DOI: 10.1002/eat.20908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
149 Basha S, Hazenfeld S, Brady RC, Subbramanian RA. Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011;72:463-9. [PMID: 21414368 DOI: 10.1016/j.humimm.2011.03.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
150 Gijzen K, Liu WM, Visontai I, Oftung F, van der Werf S, Korsvold GE, Pronk I, Aaberge IS, Tüttő A, Jankovics I, Jankovics M, Gentleman B, Mcelhaney JE, Soethout EC. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 2010;28:3416-22. [DOI: 10.1016/j.vaccine.2010.02.076] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
151 Mcelhaney JE, Coler RN, Baldwin SL. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Review of Vaccines 2014;12:759-66. [DOI: 10.1586/14760584.2013.811193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
152 Ruiz-Palacios GM, Leroux-Roels G, Beran J, Devaster JM, Esen M, Launay O, McElhaney JE, van Essen GA, Benoit A, Claeys C, Dewé W, Durand C, Duval X, Falsey AR, Feldman G, Galtier F, Gervais P, Hwang SJ, McNeil S, Richardus JH, Trofa A, Oostvogels L; Influence65 study group. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis. Hum Vaccin Immunother 2016;12:3043-55. [PMID: 27690762 DOI: 10.1080/21645515.2016.1219809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
153 Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother 2013;9:405-8. [PMID: 23291930 DOI: 10.4161/hv.22908] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 9.9] [Reference Citation Analysis]
154 Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009;30:351-9. [PMID: 19540808 DOI: 10.1016/j.it.2009.05.002] [Cited by in Crossref: 155] [Cited by in F6Publishing: 140] [Article Influence: 11.9] [Reference Citation Analysis]
155 Gaughran F, Walwyn R, Lambkin-Williams R, Whelan P, Chatterton K, Oxford J, Macdonald A; Flu-Effect of Vaccine in Elderly Residents Trial team. Flu: effect of vaccine in elderly care home residents: a randomized trial. J Am Geriatr Soc 2007;55:1912-20. [PMID: 18081669 DOI: 10.1111/j.1532-5415.2007.01471.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
156 Oshansky CM, Thomas PG. The human side of influenza. J Leukoc Biol 2012;92:83-96. [PMID: 22362872 DOI: 10.1189/jlb.1011506] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
157 de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011;96:307-14. [PMID: 20971824 DOI: 10.3324/haematol.2010.032664] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
158 Deans GD, Stiver HG, Mcelhaney JE. Influenza vaccines provide diminished protection but are cost-saving in older adults. Journal of Internal Medicine 2010;267:220-7. [DOI: 10.1111/j.1365-2796.2009.02201.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
159 de Araújo AL, Silva LC, Fernandes JR, Matias Mde S, Boas LS, Machado CM, Garcez-Leme LE, Benard G. Elderly men with moderate and intense training lifestyle present sustained higher antibody responses to influenza vaccine. Age (Dordr) 2015;37:105. [PMID: 26480853 DOI: 10.1007/s11357-015-9843-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
160 Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol 2014;5:171. [PMID: 24795718 DOI: 10.3389/fimmu.2014.00171] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 9.6] [Reference Citation Analysis]
161 Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine 2015;33:2485-92. [PMID: 25843270 DOI: 10.1016/j.vaccine.2015.03.065] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
162 Cho Y, Ahn KH, Back MJ, Choi JM, Ji JE, Won JH, Fu Z, Jang JM, Kim DK. Age-related effects of sodium arsenite on splenocyte proliferation and Th1/Th2 cytokine production. Arch Pharm Res 2012;35:375-82. [PMID: 22370793 DOI: 10.1007/s12272-012-0219-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
163 van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75-81. [PMID: 20039396 DOI: 10.1002/art.25033] [Cited by in Crossref: 212] [Cited by in F6Publishing: 183] [Article Influence: 17.7] [Reference Citation Analysis]
164 Lambe T, Spencer AJ, Mullarkey CE, Antrobus RD, Yu L, de Whalley P, Thompson BAV, Jones C, Chalk J, Kerridge S, Hill AVS, Snape MD, Pollard AJ, Gilbert SC. T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent–inactivated Influenza Vaccine. Pediatric Infectious Disease Journal 2012;31:e86-91. [DOI: 10.1097/inf.0b013e318255e443] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
165 Baer J, Santiago F, Yang H, Wu H, Holden-Wiltse J, Treanor J, Topham DJ. B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine 2010;28:907-15. [PMID: 19932673 DOI: 10.1016/j.vaccine.2009.11.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
166 Chiu HT, Shen LJ, Chen YC, Lin JH, Wang CC. Effect of statin use on the risk of medically attended acute respiratory illness among influenza vaccinated elderly. Vaccine 2018;36:6133-7. [PMID: 30174239 DOI: 10.1016/j.vaccine.2018.08.067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
167 Curran MP, Leroux-Roels I. Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs 2010;70:1519-43. [PMID: 20687619 DOI: 10.2165/11205020-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
168 Lang P, Bonduelle O, Benhabiles N, Combadiere B. Prior contacts with the 2000–2003 seasonal vaccines extends the 2009 pandemic A/H1N1 vaccine-specific immune protection to non-humoral compartments. European Geriatric Medicine 2014;5:136-8. [DOI: 10.1016/j.eurger.2014.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
169 Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010;28:6145-51. [PMID: 20646987 DOI: 10.1016/j.vaccine.2010.07.036] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
170 Benoit A, Legrand C, Dewé W. Influenza vaccine efficacy trials: a simulation approach to understand failures from the past. Pharm Stat 2015;14:294-301. [PMID: 25924929 DOI: 10.1002/pst.1685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine. 2008;26 Suppl 4:D35-D40. [PMID: 19230157 DOI: 10.1016/j.vaccine.2008.07.065] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
172 Scheible K, Zhang G, Baer J, Azadniv M, Lambert K, Pryhuber G, Treanor JJ, Topham DJ. CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine 2011;29:2159-68. [PMID: 21211588 DOI: 10.1016/j.vaccine.2010.12.073] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
173 Liu WM, Nahar TE, Jacobi RH, Gijzen K, van Beek J, Hak E, Jonges M, Boog CJ, van der Zeijst BA, Soethout EC. Impaired production of TNF-α by dendritic cells of older adults leads to a lower CD8+ T cell response against influenza. Vaccine 2012;30:1659-66. [PMID: 22230585 DOI: 10.1016/j.vaccine.2011.12.105] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
174 Livingston BD, Higgins D, Van Nest G. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 2006;20:335-40. [PMID: 17176120 DOI: 10.2165/00063030-200620060-00003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
175 Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, Nichol KL, Puig-Barberà J, Schmitt J, Stephenson I. Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 2009;27:5043-53. [PMID: 19559118 DOI: 10.1016/j.vaccine.2009.06.032] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 6.9] [Reference Citation Analysis]
176 Huang P, Yu S, Wu C, Liang L. Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations. J Transl Med 2013;11:47. [PMID: 23433453 DOI: 10.1186/1479-5876-11-47] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
177 Chen Y, Li C, Liu F, Ye Z, Song W, Lee ACY, Shuai H, Lu L, To KK, Chan JF, Zhang AJ, Chu H, Yuen KY. Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in mouse model. Emerg Microbes Infect 2022;:1-36. [PMID: 34989330 DOI: 10.1080/22221751.2022.2026741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
178 Samy RP, Lim LH. DAMPs and influenza virus infection in ageing. Ageing Res Rev 2015;24:83-97. [PMID: 26200296 DOI: 10.1016/j.arr.2015.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
179 Valkenburg SA, Leung NHL, Bull MB, Yan LM, Li APY, Poon LLM, Cowling BJ. The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine. Front Immunol 2018;9:1479. [PMID: 30013557 DOI: 10.3389/fimmu.2018.01479] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
180 Sridhar S. Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines. Front Immunol 2016;7:195. [PMID: 27242800 DOI: 10.3389/fimmu.2016.00195] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
181 Thomas-Crusells J, McElhaney JE, Aguado MT. Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization. Vaccine 2012;30:6007-12. [PMID: 22835737 DOI: 10.1016/j.vaccine.2012.07.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
182 Lv J, Ren ZY, Zhang YY, Liu YE, Gao J, Yao K, Feng D, Li ZY, Feng X, Liu YX, Jia N. Study on age-dependent pre-existing 2009 pandemic influenza virus T and B cell responses from Chinese population. BMC Infect Dis 2017;17:136. [PMID: 28187750 DOI: 10.1186/s12879-017-2215-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
183 Rüthrich MM, Giesen N, Mellinghoff SC, Rieger CT, von Lilienfeld-toal M. Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences. Vaccines 2022;10:182. [DOI: 10.3390/vaccines10020182] [Reference Citation Analysis]
184 Chi CY, Liu CC, Lin CC, Wang HC, Cheng YT, Chang CM, Wang JR. Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 2010;17:1958-62. [PMID: 20876823 DOI: 10.1128/CVI.00212-10] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
185 Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Opinion on Biological Therapy 2009;10:191-200. [DOI: 10.1517/14712590903431014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
186 Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013;12:519-36. [PMID: 23659300 DOI: 10.1586/erv.13.35] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 9.1] [Reference Citation Analysis]
187 Weinfurter JT, Brunner K, Capuano SV 3rd, Li C, Broman KW, Kawaoka Y, Friedrich TC. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 2011;7:e1002381. [PMID: 22102819 DOI: 10.1371/journal.ppat.1002381] [Cited by in Crossref: 119] [Cited by in F6Publishing: 115] [Article Influence: 10.8] [Reference Citation Analysis]
188 Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, Webster RG. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 2009;27:4187-95. [PMID: 19406182 DOI: 10.1016/j.vaccine.2009.04.050] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
189 Pellegrino P, Clementi E, Capuano A, Radice S. Can vaccines interact with drug metabolism? Pharmacological Research 2015;92:13-7. [DOI: 10.1016/j.phrs.2014.09.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
190 Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, Sertoli MR, Balleari E, Racchi O, Messina M, Caltabiano G, Icardi G, Durando P, Marincola FM, Boccardo F, Ferrarini M, Ansaldi F, De Maria A. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011;186:6044-55. [PMID: 21498665 DOI: 10.4049/jimmunol.1004095] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
191 Cortese M, Sherman AC, Rouphael NG, Pulendran B. Systems Biological Analysis of Immune Response to Influenza Vaccination. Cold Spring Harb Perspect Med 2021;11:a038596. [PMID: 32152245 DOI: 10.1101/cshperspect.a038596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
192 Bodewes R, Fraaij PL, Geelhoed-Mieras MM, van Baalen CA, Tiddens HA, van Rossum AM, van der Klis FR, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children. J Virol 2011;85:11995-2000. [PMID: 21880755 DOI: 10.1128/JVI.05213-11] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
193 Rungrojcharoenkit K, Sunintaboon P, Ellison D, Macareo L, Midoeng P, Chaisuwirat P, Fernandez S, Ubol S. Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study. PLoS One 2020;15:e0237218. [PMID: 32760143 DOI: 10.1371/journal.pone.0237218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
194 Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012;30:4907-20. [PMID: 22658928 DOI: 10.1016/j.vaccine.2012.05.049] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 11.0] [Reference Citation Analysis]
195 Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010;33:516-529. [PMID: 21029962 DOI: 10.1016/j.immuni.2010.10.006] [Cited by in Crossref: 262] [Cited by in F6Publishing: 232] [Article Influence: 21.8] [Reference Citation Analysis]
196 Schmid P, Selak S, Keller M, Luhan B, Magyarics Z, Seidel S, Schlick P, Reinisch C, Lingnau K, Nagy E, Grubeck-Loebenstein B. Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age. Vaccine 2011;29:3982-9. [PMID: 21481328 DOI: 10.1016/j.vaccine.2011.03.081] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
197 Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013;33:388-96. [PMID: 23064976 DOI: 10.1007/s10875-012-9813-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
198 Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Lechmere T, Malim MH, Meynell F, Pollock E, Seow J, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree TIM, Smith CH. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol 2021;3:e627-37. [PMID: 34258590 DOI: 10.1016/S2665-9913(21)00212-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
199 Agrati C, Gioia C, Castilletti C, Lapa D, Berno G, Puro V, Carletti F, Cimini E, Nisii C, Castellino F, Martini F, Capobianchi MR. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. AIDS Res Hum Retroviruses 2012;28:1606-16. [PMID: 22439734 DOI: 10.1089/AID.2011.0371] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
200 Ng TWY, Cowling BJ, Gao HZ, Thompson MG. Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis. J Infect Dis 2019;219:1525-35. [PMID: 30551178 DOI: 10.1093/infdis/jiy720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
201 Weinberg A, Song LY, Fenton T, Nachman SA, Read JS, Patterson-Bartlett J, Levin MJ. T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. AIDS Res Hum Retroviruses 2010;26:51-9. [PMID: 20059397 DOI: 10.1089/aid.2009.0163] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
202 Hayney MS, Coe CL, Muller D, Obasi CN, Backonja U, Ewers T, Barrett B. Age and psychological influences on immune responses to trivalent inactivated influenza vaccine in the meditation or exercise for preventing acute respiratory infection (MEPARI) trial. Hum Vaccin Immunother 2014;10:83-91. [PMID: 24096366 DOI: 10.4161/hv.26661] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
203 Scaglione A, Opp S, Hurtado A, Lin Z, Pampeno C, Noval MG, Thannickal SA, Stapleford KA, Meruelo D. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. Front Immunol 2021;12:719077. [PMID: 34394127 DOI: 10.3389/fimmu.2021.719077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
204 Silva-Cayetano A, Foster WS, Innocentin S, Belij-Rammerstorfer S, Spencer AJ, Burton OT, Fra-Bidó S, Le Lee J, Thakur N, Conceicao C, Wright D, Barrett J, Evans-Bailey N, Noble C, Bailey D, Liston A, Gilbert SC, Lambe T, Linterman MA. A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med (N Y) 2021;2:243-262.e8. [PMID: 33521747 DOI: 10.1016/j.medj.2020.12.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
205 Subbramanian RA, Basha S, Brady RC, Hazenfeld S, Shata MT, Bernstein DI. Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Human Immunology 2010;71:957-63. [DOI: 10.1016/j.humimm.2010.07.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
206 Xu C, Thompson MG, Cowling BJ. Influenza vaccination in tropical and subtropical areas. Lancet Respir Med 2017;5:920-2. [PMID: 29066091 DOI: 10.1016/S2213-2600(17)30377-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
207 McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012;30:2060-7. [PMID: 22289511 DOI: 10.1016/j.vaccine.2012.01.015] [Cited by in Crossref: 161] [Cited by in F6Publishing: 140] [Article Influence: 16.1] [Reference Citation Analysis]
208 Ren ST, Zhang XM, Sun PF, Sun LJ, Guo X, Tian T, Zhang J, Guo QY, Li X, Guo LJ, Che J, Wang B, Zhang H. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59. PLoS One 2017;12:e0169501. [PMID: 28052136 DOI: 10.1371/journal.pone.0169501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
209 Pawelec G, McElhaney J. Vaccines for Improved Cellular Immunity to Influenza. EBioMedicine 2018;30:12-3. [PMID: 29525573 DOI: 10.1016/j.ebiom.2018.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
210 Kumar A, McElhaney JE, Walrond L, Cyr TD, Merani S, Kollmann TR, Halperin SA, Scheifele DW. Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison. Hum Vaccin Immunother 2017;13:2048-57. [PMID: 28635557 DOI: 10.1080/21645515.2017.1337615] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
211 Subbramanian RA, Basha S, Shata MT, Brady RC, Bernstein DI. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 2010;28:8258-67. [DOI: 10.1016/j.vaccine.2010.10.077] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
212 Toy R, Keenum MC, Pradhan P, Phang K, Chen P, Chukwu C, Nguyen LAH, Liu J, Jain S, Kozlowski G, Hosten J, Suthar MS, Roy K. TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination. J Control Release 2021;330:866-77. [PMID: 33160004 DOI: 10.1016/j.jconrel.2020.10.060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
213 Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 2012;30:4655-60. [PMID: 22575166 DOI: 10.1016/j.vaccine.2012.04.089] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
214 Meng Z, Zhang J, Shi J, Zhao W, Huang X, Cheng L, Yang X. Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness. Hum Vaccin Immunother 2020;16:2680-9. [PMID: 32347787 DOI: 10.1080/21645515.2020.1747375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Manuela Q, Gianbattista L, Gianpiero L, Antonella de D. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers in South Apulia, Italy: a pilot study. J Clin Med Res 2011;3:291-5. [PMID: 22393340 DOI: 10.4021/jocmr647w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009;83:4624-30. [PMID: 19211745 DOI: 10.1128/JVI.02335-08] [Cited by in Crossref: 98] [Cited by in F6Publishing: 66] [Article Influence: 7.5] [Reference Citation Analysis]
217 McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol 2010;8:37. [PMID: 20385031 DOI: 10.1186/1741-7007-8-37] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
218 Goldeck D, Theeten H, Hassouneh F, Oettinger L, Wistuba-Hamprecht K, Cools N, Tsitsilonis OE, Pawelec G. Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine. Vaccine 2017;35:4330-8. [PMID: 28689651 DOI: 10.1016/j.vaccine.2017.06.082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
219 Powell TJ, Fox A, Peng Y, Quynh Mai le T, Lien VT, Hang NL, Wang L, Lee LY, Simmons CP, McMichael AJ, Farrar JJ, Askonas BA, Duong TN, Thai PQ, Thu Yen NT, Rowland-Jones SL, Hien NT, Horby P, Dong T. Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections. J Infect Dis 2012;205:20-7. [PMID: 22080094 DOI: 10.1093/infdis/jir689] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
220 Yung BS, Pugh H, Generotti AA, Phanhthilath N, Schultheis K, Muthumani K, Broderick KE, Smith TRF. Novel IFN-γ ELISpot reveals robust T cell responses elicited after influenza nucleoprotein DNA vaccination in New Zealand White rabbits. Vaccine 2019;37:903-9. [PMID: 30661837 DOI: 10.1016/j.vaccine.2019.01.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Shaw SM, Williams SG, Yonan N, Fildes JE. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail 2009;15:549; author reply 549-51. [PMID: 19643367 DOI: 10.1016/j.cardfail.2009.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Cowling BJ, Perera RAPM, Valkenburg SA, Leung NHL, Iuliano AD, Tam YH, Wong JHF, Fang VJ, Li APY, So HC, Ip DKM, Azziz-Baumgartner E, Fry AM, Levine MZ, Gangappa S, Sambhara S, Barr IG, Skowronski DM, Peiris JSM, Thompson MG. Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clin Infect Dis 2020;71:1704-14. [PMID: 31828291 DOI: 10.1093/cid/ciz1034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
223 Jia N, Li C, Liu Y, Richardus JH, Feng D, Yang H, Dang R, Ma Y, Xu X, Cao W. Lower cellular immune responses to influenza A (H3N2) in the elderly. J Med Virol 2009;81:1471-6. [DOI: 10.1002/jmv.21544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
224 Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009;21:201-9. [PMID: 19571643 DOI: 10.1007/BF03324904] [Cited by in Crossref: 194] [Cited by in F6Publishing: 96] [Article Influence: 14.9] [Reference Citation Analysis]
225 Parpaleix A, Boyer L, Wiedemann A, Lacabaratz C, Margarit L, Enouf V, Le Corvoisier P, Lino A, Covali-Noroc A, Housset B, Chouaid C, Maitre B, Lévy Y, Lelièvre JD, Adnot S. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J Allergy Clin Immunol 2017;140:1754-1757.e6. [PMID: 28889955 DOI: 10.1016/j.jaci.2017.07.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
226 Kim C, Fang F, Weyand CM, Goronzy JJ. The life cycle of a T cell after vaccination - where does immune ageing strike? Clin Exp Immunol 2017;187:71-81. [PMID: 27324743 DOI: 10.1111/cei.12829] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
227 Kim JH, Talbot HK, Mishina M, Zhu Y, Chen J, Cao W, Reber AJ, Griffin MR, Shay DK, Spencer SM, Sambhara S. High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses. Vaccine 2016;34:4594-601. [PMID: 27473306 DOI: 10.1016/j.vaccine.2016.07.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
228 Radošević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Vaccine 2008;26:3640-6. [DOI: 10.1016/j.vaccine.2008.04.071] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
229 Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol 2009;333:413-29. [PMID: 19768417 DOI: 10.1007/978-3-540-92165-3_20] [Cited by in Crossref: 34] [Cited by in F6Publishing: 53] [Article Influence: 2.6] [Reference Citation Analysis]
230 Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, Chan PL, Lam KT, Guan J, Zhang L, Guan Y, Yuen KY, Peiris JS, Lau YL. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010;84:6527-35. [PMID: 20410263 DOI: 10.1128/JVI.00519-10] [Cited by in Crossref: 118] [Cited by in F6Publishing: 82] [Article Influence: 9.8] [Reference Citation Analysis]
231 Sieiro Santos C, Calleja Antolin S, Moriano Morales C, Garcia Herrero J, Diez Alvarez E, Ramos Ortega F, Ruiz de Morales JG. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open 2022;8:e001898. [PMID: 34987093 DOI: 10.1136/rmdopen-2021-001898] [Reference Citation Analysis]
232 Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009;60:2438-47. [PMID: 19644961 DOI: 10.1002/art.24679] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
233 Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L, Humar A. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. Transplantation 2016;100:662-9. [PMID: 26335915 DOI: 10.1097/TP.0000000000000861] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 7.2] [Reference Citation Analysis]
234 Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis 2015;60:1170-5. [PMID: 25697739 DOI: 10.1093/cid/civ019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
235 Min D, Panoskaltsis-Mortari A, Kuro-O M, Holländer GA, Blazar BR, Weinberg KI. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood 2007;109:2529-37. [PMID: 17138819 DOI: 10.1182/blood-2006-08-043794] [Cited by in Crossref: 145] [Cited by in F6Publishing: 134] [Article Influence: 9.1] [Reference Citation Analysis]
236 Kennedy RB, Ovsyannikova IG, Haralambieva IH, Oberg AL, Zimmermann MT, Grill DE, Poland GA. Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination. Front Immunol 2016;7:450. [PMID: 27853459 DOI: 10.3389/fimmu.2016.00450] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
237 Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people – Authors' reply. The Lancet Infectious Diseases 2008;8:463-5. [DOI: 10.1016/s1473-3099(08)70164-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
238 Kohut ML. Immune Function: Impact of Exercise and Nutritional Interventions. Am J Lifestyle Med 2016;10:174-7. [PMID: 30202270 DOI: 10.1177/1559827616631723] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
239 Fraser CS, Jha A, Openshaw PJ. Vaccines in the Prevention of Viral Pneumonia. Clin Chest Med 2017;38:155-69. [PMID: 28159157 DOI: 10.1016/j.ccm.2016.11.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
240 Macleod MK, David A, Jin N, Noges L, Wang J, Kappler JW, Marrack P. Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One 2013;8:e61775. [PMID: 23613928 DOI: 10.1371/journal.pone.0061775] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
241 Fiore AE, Bridges CB, Katz JM, Cox NJ. Inactivated influenza vaccines. Vaccines. Elsevier; 2013. pp. 257-93. [DOI: 10.1016/b978-1-4557-0090-5.00026-4] [Cited by in Crossref: 18] [Article Influence: 2.0] [Reference Citation Analysis]
242 Targonski PV, Caldwell CR, Strausbauch M, Wettstein P, Poland GA, Tangalos EG. White blood cell telomerase activity and incident respiratory illness among community-dwelling elderly vaccinated against seasonal influenza. Clin Pharmacol Ther 2007;82:694-9. [PMID: 17971815 DOI: 10.1038/sj.clpt.6100410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
243 Won S, Hunt K, Guak H, Hasaj B, Charland N, Landry N, Ward BJ, Krawczyk CM. Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin. Vaccine 2018;36:8028-38. [DOI: 10.1016/j.vaccine.2018.10.099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
244 Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, Bruzil S, Haima KY, Gottlieb T, Ben-Yedidia T. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine 2014;32:5816-23. [PMID: 25173483 DOI: 10.1016/j.vaccine.2014.08.031] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 7.0] [Reference Citation Analysis]
245 Nichol KL. Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy. Vaccine 2009;27:6305-11. [DOI: 10.1016/j.vaccine.2009.07.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
246 Selmi C, Leung PS, Fischer L, German B, Yang CY, Kenny TP, Cysewski GR, Gershwin ME. The effects of Spirulina on anemia and immune function in senior citizens. Cell Mol Immunol 2011;8:248-54. [PMID: 21278762 DOI: 10.1038/cmi.2010.76] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
247 Vardeny O, Sweitzer NK, Detry MA, Moran JM, Johnson MR, Hayney MS. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail 2009;15:368-73. [PMID: 19398087 DOI: 10.1016/j.cardfail.2008.11.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
248 Lee YN, Lee YT, Kim MC, Hwang HS, Lee JS, Kim KH, Kang SM. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology 2014;143:300-9. [PMID: 24773389 DOI: 10.1111/imm.12310] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
249 Gil A, Yassai MB, Naumov YN, Selin LK. Narrowing of human influenza A virus-specific T cell receptor α and β repertoires with increasing age. J Virol 2015;89:4102-16. [PMID: 25609818 DOI: 10.1128/JVI.03020-14] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
250 Manuel O, Humar A, Chen MH, Chernenko S, Singer LG, Cobos I, Kumar D. Immunogenicity and Safety of an Intradermal Boosting Strategy for Vaccination Against Influenza in Lung Transplant Recipients. Am J Transplant 2007;7:2567-72. [DOI: 10.1111/j.1600-6143.2007.01982.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
251 Cukalac T, Chadderton J, Zeng W, Cullen JG, Kan WT, Doherty PC, Jackson DC, Turner SJ, La Gruta NL. The Influenza Virus–Specific CTL Immunodominance Hierarchy in Mice Is Determined by the Relative Frequency of High-Avidity T Cells. J I 2014;192:4061-8. [DOI: 10.4049/jimmunol.1301403] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
252 Metz B, van den Dobbelsteen G, van Els C, van der Gun J, Levels L, van der Pol L, Rots N, Kersten G. Quality-control issues and approaches in vaccine development. Expert Review of Vaccines 2014;8:227-38. [DOI: 10.1586/14760584.8.2.227] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
253 Steeper M, Plebanski M, Flanagan KL. The global challenge and future strategies for keeping the world's aging population healthy by vaccination. Trans R Soc Trop Med Hyg 2016;110:427-31. [PMID: 27618919 DOI: 10.1093/trstmh/trw054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
254 Bufan B, Arsenović-Ranin N, Živković I, Petrović R, Leposavić G. B-cell response to seasonal influenza vaccine in mice is amenable to pharmacological modulation through β-adrenoceptor. Life Sci 2022;301:120617. [PMID: 35533760 DOI: 10.1016/j.lfs.2022.120617] [Reference Citation Analysis]
255 Puig-barberà J, Natividad-sancho A, Calabuig-pérez J, Lluch-rodrigo J, Pastor-villalba E, Martínez-úbeda S, Pérez-vilar S, Díez-domingo J. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system. Vaccine 2013;31:3995-4002. [DOI: 10.1016/j.vaccine.2013.05.070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
256 Co MD, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, Leporati AM, Babon JA, Evans JE, Ennis FA, Terajima M. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 2009;27:319-27. [PMID: 18977404 DOI: 10.1016/j.vaccine.2008.09.092] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
257 Zhao M, Chen J, Tan S, Dong T, Jiang H, Zheng J, Quan C, Liao Q, Zhang H, Wang X, Wang Q, Bi Y, Liu F, Feng L, Horby PW, Klenerman P, Gao GF, Liu WJ, Yu H. Prolonged Evolution of Virus-Specific Memory T Cell Immunity after Severe Avian Influenza A (H7N9) Virus Infection. J Virol 2018;92:e01024-18. [PMID: 29925664 DOI: 10.1128/JVI.01024-18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
258 Lorenzo EC, Bartley JM, Haynes L. The impact of aging on CD4+ T cell responses to influenza infection. Biogerontology 2018;19:437-46. [PMID: 29616390 DOI: 10.1007/s10522-018-9754-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
259 Mieves JF, Wittke K, Freitag H, Volk HD, Scheibenbogen C, Hanitsch LG. Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID). Curr Allergy Asthma Rep 2017;17:78. [PMID: 28983790 DOI: 10.1007/s11882-017-0749-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
260 Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010;10:18. [PMID: 20210985 DOI: 10.1186/1471-2288-10-18] [Cited by in Crossref: 212] [Cited by in F6Publishing: 199] [Article Influence: 17.7] [Reference Citation Analysis]
261 Almanan M, Raynor J, Ogunsulire I, Malyshkina A, Mukherjee S, Hummel SA, Ingram JT, Saini A, Xie MM, Alenghat T, Way SS, Deepe GS Jr, Divanovic S, Singh H, Miraldi E, Zajac AJ, Dent AL, Hölscher C, Chougnet C, Hildeman DA. IL-10-producing Tfh cells accumulate with age and link inflammation with age-related immune suppression. Sci Adv 2020;6:eabb0806. [PMID: 32832688 DOI: 10.1126/sciadv.abb0806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
262 Francis JN, Bunce CJ, Horlock C, Watson JM, Warrington SJ, Georges B, Brown CB. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine 2015;33:396-402. [PMID: 24928790 DOI: 10.1016/j.vaccine.2014.06.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
263 Cookenham T, Lanzer KG, Gage E, Lorenzo EC, Carter D, Coler RN, Baldwin SL, Haynes L, Reiley WW, Blackman MA. Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity. Vaccine 2020;38:5256-67. [PMID: 32540272 DOI: 10.1016/j.vaccine.2020.05.085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
264 Wu C, Zanker D, Valkenburg S, Tan B, Kedzierska K, Zou QM, Doherty PC, Chen W. Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals. Proc Natl Acad Sci U S A 2011;108:9178-83. [PMID: 21562214 DOI: 10.1073/pnas.1105624108] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
265 Tscharke DC, Croft NP, Doherty PC, La Gruta NL. Sizing up the key determinants of the CD8+ T cell response. Nat Rev Immunol 2015;15:705-16. [DOI: 10.1038/nri3905] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 12.1] [Reference Citation Analysis]
266 Kolpe A, Schepens B, Fiers W, Saelens X. M2-based influenza vaccines: recent advances and clinical potential. Expert Review of Vaccines 2017;16:123-36. [DOI: 10.1080/14760584.2017.1240041] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 10.3] [Reference Citation Analysis]
267 McElhaney JE, Andrew MK, McNeil SA. Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults. Vaccine 2017;35:6269-74. [PMID: 29032898 DOI: 10.1016/j.vaccine.2017.09.084] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
268 Trzonkowski P, Myśliwska J, Pawelec G, Myśliwski A. From bench to bedside and back: the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology 2009;10:83-94. [DOI: 10.1007/s10522-008-9155-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
269 McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev 2011;10:379-88. [PMID: 21055484 DOI: 10.1016/j.arr.2010.10.008] [Cited by in Crossref: 115] [Cited by in F6Publishing: 111] [Article Influence: 10.5] [Reference Citation Analysis]
270 Sun H, Fei L, Zhu B, Shi M. Quick and improved immune responses to inactivated H9N2 avian influenza vaccine by purified active fraction of Albizia julibrissin saponins. BMC Vet Res 2020;16:427. [PMID: 33160337 DOI: 10.1186/s12917-020-02648-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Pawelec G, McElhaney JE, Aiello AE, Derhovanessian E. The impact of CMV infection on survival in older humans. Curr Opin Immunol 2012;24:507-11. [PMID: 22541724 DOI: 10.1016/j.coi.2012.04.002] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 8.9] [Reference Citation Analysis]
272 Vardeny O, Moran JJ, Sweitzer NK, Johnson MR, Hayney MS. Decreased T-cell responses to influenza vaccination in patients with heart failure. Pharmacotherapy 2010;30:10-6. [PMID: 20030468 DOI: 10.1592/phco.30.1.10] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
273 Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS 2011;15:625-36. [PMID: 21732819 DOI: 10.1089/omi.2011.0032] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
274 Wijnans L, Voordouw B. A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir Viruses 2016;10:2-8. [PMID: 26439108 DOI: 10.1111/irv.12351] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
275 Mifsud EJ, Tan AC, Jackson DC. TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease. Front Immunol 2014;5:79. [PMID: 24624130 DOI: 10.3389/fimmu.2014.00079] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 10.3] [Reference Citation Analysis]
276 Castrucci MR. Factors affecting immune responses to the influenza vaccine. Hum Vaccin Immunother 2018;14:637-46. [PMID: 28617077 DOI: 10.1080/21645515.2017.1338547] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
277 Bartley JM, Cadar AN, Martin DE. Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults. Immunol Invest 2021;50:810-20. [PMID: 33830864 DOI: 10.1080/08820139.2021.1909617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Mansiaux Y, Salez N, Lapidus N, Setbon M, Andreoletti L, Leruez-Ville M, Cauchemez S, Gougeon ML, Vély F, Schwarzinger M, Abel L, Delabre RM, Flahault A, de Lamballerie X, Carrat F. Causal analysis of H1N1pdm09 influenza infection risk in a household cohort. J Epidemiol Community Health 2015;69:272-7. [PMID: 25416792 DOI: 10.1136/jech-2014-204678] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
279 Cowling BJ, Lim WW, Perera RAPM, Fang VJ, Leung GM, Peiris JSM, Tchetgen Tchetgen EJ. Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B. Clin Infect Dis 2019;68:1713-7. [PMID: 30202873 DOI: 10.1093/cid/ciy759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
280 Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011;9:669-83. [PMID: 21692672 DOI: 10.1586/eri.11.51] [Cited by in Crossref: 154] [Cited by in F6Publishing: 151] [Article Influence: 14.0] [Reference Citation Analysis]
281 Ramirez LA, Daniel A, Frank I, Tebas P, Boyer JD. Seroprotection of HIV-infected subjects after influenza A(H1N1) vaccination is directly associated with baseline frequency of naive T cells. J Infect Dis 2014;210:646-50. [PMID: 24610877 DOI: 10.1093/infdis/jiu132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
282 Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12:509-517. [PMID: 21739679 DOI: 10.1038/ni.2039] [Cited by in Crossref: 546] [Cited by in F6Publishing: 496] [Article Influence: 49.6] [Reference Citation Analysis]
283 L'huillier AG, Ferreira VH, Hirzel C, Natori Y, Slomovic J, Ku T, Hoschler K, Ierullo M, Selzner N, Schiff J, Singer LG, Humar A, Kumar D. Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial. J Infect Dis 2020;221:53-62. [PMID: 31550354 DOI: 10.1093/infdis/jiz471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
284 Carre C, Wong G, Narang V, Tan C, Chong J, Chin HX, Xu W, Lu Y, Chua M, Poidinger M, Tambyah P, Nyunt M, Ng TP, Larocque D, Hessler C, Bosco N, Quemeneur L, Larbi A. Endoplasmic reticulum stress response and bile acid signatures associate with multi-strain seroresponsiveness during elderly influenza vaccination. iScience 2021;24:102970. [PMID: 34471863 DOI: 10.1016/j.isci.2021.102970] [Reference Citation Analysis]
285 Lang P, Govind S, Mitchell W, Kenny N, Lapenna A, Pitts D, Aspinall R. Influenza vaccine effectiveness in aged individuals: The role played by cell-mediated immunity. European Geriatric Medicine 2010;1:233-8. [DOI: 10.1016/j.eurger.2010.07.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
286 Shim SM, Song EJ, Song D, Lee TY, Kim DJ, Nam JH, Gwin Jeong D, Lee CK, Kim SH, Kim JK. Nontoxic outer membrane vesicles efficiently increase the efficacy of an influenza vaccine in mice and ferrets. Vaccine 2017;35:3741-8. [PMID: 28576571 DOI: 10.1016/j.vaccine.2017.05.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
287 Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, Lu X, DeVos J, Hancock K, Katz JM, Vedvick TS, Duthie MS, Clegg CH, Van Hoeven N, Reed SG. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 2010;5:e13677. [PMID: 21060869 DOI: 10.1371/journal.pone.0013677] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 8.9] [Reference Citation Analysis]
288 Enani S, Przemska-Kosicka A, Childs CE, Maidens C, Dong H, Conterno L, Tuohy K, Todd S, Gosney M, Yaqoob P. Impact of ageing and a synbiotic on the immune response to seasonal influenza vaccination; a randomised controlled trial. Clin Nutr 2018;37:443-51. [PMID: 28215759 DOI: 10.1016/j.clnu.2017.01.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
289 Rees-spear C, Mccoy LE. Vaccine responses in ageing and chronic viral infection. Oxford Open Immunology 2021;2:iqab007. [DOI: 10.1093/oxfimm/iqab007] [Reference Citation Analysis]
290 Qi Q, Cavanagh MM, Le Saux S, Wagar LE, Mackey S, Hu J, Maecker H, Swan GE, Davis MM, Dekker CL, Tian L, Weyand CM, Goronzy JJ. Defective T Memory Cell Differentiation after Varicella Zoster Vaccination in Older Individuals. PLoS Pathog 2016;12:e1005892. [PMID: 27764254 DOI: 10.1371/journal.ppat.1005892] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
291 Skibinski DA, Hanson BJ, Lin Y, von Messling V, Jegerlehner A, Tee JB, Chye de H, Wong SK, Ng AA, Lee HY, Au B, Lee BT, Santoso L, Poidinger M, Fairhurst AM, Matter A, Bachmann MF, Saudan P, Connolly JE. Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS One 2013;8:e76571. [PMID: 24204639 DOI: 10.1371/journal.pone.0076571] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
292 Pereira B, Xu XN, Akbar AN. Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. Front Immunol 2020;11:583019. [PMID: 33178213 DOI: 10.3389/fimmu.2020.583019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
293 Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG, Barrett PN. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007;25:6028-36. [PMID: 17614165 DOI: 10.1016/j.vaccine.2007.05.013] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
294 Ayling K, Vedhara K, Fairclough L. Measuring Vaccine Responses in the Multiplex Era. Methods Mol Biol 2018;1781:327-40. [PMID: 29705855 DOI: 10.1007/978-1-4939-7828-1_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
295 Duvvuri VR, Moghadas SM, Guo H, Duvvuri B, Heffernan JM, Fisman DN, Wu GE, Wu J. Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses. Influenza Other Respir Viruses 2010;4:249-58. [PMID: 20716156 DOI: 10.1111/j.1750-2659.2010.00161.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
296 Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC, Kollmann TR, Reed SG, McElhaney JE. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis 2012;205:466-73. [PMID: 22147791 DOI: 10.1093/infdis/jir769] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 8.5] [Reference Citation Analysis]
297 Gillard P, Giet D, Heijmans S, Dramé M, Walravens K, Roman F. Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study. Trials 2014;15:419. [PMID: 25354581 DOI: 10.1186/1745-6215-15-419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
298 Eiden J, Gordon G, Fierro C, Herber R, Aitchison R, Belshe R, Greenberg H, Hoft D, Hatta Y, Moser MJ, Tary-Lehmann M, Kawaoka Y, Neumann G, Radspinner P, Bilsel P. Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults. Vaccines (Basel) 2021;9:1388. [PMID: 34960134 DOI: 10.3390/vaccines9121388] [Reference Citation Analysis]
299 Hatzifoti C, Heath AW. CD40-mediated enhancement of immune responses against three forms of influenza vaccine. Immunology 2007;122:98-106. [PMID: 17472718 DOI: 10.1111/j.1365-2567.2007.02617.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
300 Theeten H, Mathei C, Peeters K, Ogunjimi B, Goossens H, Ieven M, Van Damme P, Cools N. Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly. Viral Immunol 2016;29:169-75. [PMID: 27002465 DOI: 10.1089/vim.2015.0071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
301 Kang KS, Lee N, Shin MS, Kim SD, Yu Y, Mohanty S, Belshe RB, Montgomery RR, Shaw AC, Kang I. An altered relationship of influenza vaccine-specific IgG responses with T cell immunity occurs with aging in humans. Clin Immunol 2013;147:79-88. [PMID: 23578549 DOI: 10.1016/j.clim.2013.02.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
302 Mbawuike IN, Atmar RL, Patel SM, Corry DB, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB Jr, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA. Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine 2016;34:547-54. [PMID: 26657997 DOI: 10.1016/j.vaccine.2015.11.055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
303 Teo SP. Review of COVID-19 Vaccines and Their Evidence in Older Adults. Ann Geriatr Med Res 2021;25:4-9. [PMID: 33550776 DOI: 10.4235/agmr.21.0011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
304 Montomoli E, Torelli A, Manini I, Gianchecchi E. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults. Vaccines (Basel) 2018;6:E14. [PMID: 29518013 DOI: 10.3390/vaccines6010014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
305 Sławin A, Brydak LB, Doniec Z, Bujnowska-Fedak M, Mastalerz-Migas A. Serum Vitamin D and Immunogenicity of Influenza Vaccination in the Elderly. Adv Exp Med Biol 2021;1324:21-8. [PMID: 32946038 DOI: 10.1007/5584_2020_580] [Reference Citation Analysis]
306 Voigt EA, Ovsyannikova IG, Kennedy RB, Grill DE, Goergen KM, Schaid DJ, Poland GA. Sex Differences in Older Adults' Immune Responses to Seasonal Influenza Vaccination. Front Immunol 2019;10:180. [PMID: 30873150 DOI: 10.3389/fimmu.2019.00180] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
307 Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. medRxiv 2021:2021. [PMID: 34013294 DOI: 10.1101/2021.05.10.21256634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
308 Coudeville L, Andre P, Bailleux F, Weber F, Plotkin S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin 2010;6:841-8. [PMID: 20930559 DOI: 10.4161/hv.6.10.12636] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
309 Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, Chan T, Gentleman B, Purych D, Gardy J, Patrick DM, Brunham RC, De Serres G, Petric M. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 2011;203:158-67. [PMID: 21288814 DOI: 10.1093/infdis/jiq039] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 6.3] [Reference Citation Analysis]
310 Li X, Miao H, Henn A, Topham DJ, Wu H, Zand MS, Mosmann TR. Ki-67 expression reveals strong, transient influenza specific CD4 T cell responses after adult vaccination. Vaccine 2012;30:4581-4. [PMID: 22554464 DOI: 10.1016/j.vaccine.2012.04.059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
311 Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008;26 Suppl 4:D41-4. [PMID: 19230158 DOI: 10.1016/j.vaccine.2008.07.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
312 Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing 2008;5:11. [PMID: 18816370 DOI: 10.1186/1742-4933-5-11] [Cited by in Crossref: 101] [Cited by in F6Publishing: 81] [Article Influence: 7.2] [Reference Citation Analysis]
313 Huang CH, Huang CY, Cheng CP, Dai SH, Chen HW, Leng CH, Chong P, Liu SJ, Huang MH. Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy. Sci Rep 2016;6:36732. [PMID: 27827451 DOI: 10.1038/srep36732] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
314 McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G. The immune response to influenza in older humans: beyond immune senescence. Immun Ageing 2020;17:10. [PMID: 32399058 DOI: 10.1186/s12979-020-00181-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
315 Lang P, Mitchell W, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main age-related diseases and frailty: Role of immunosenescence. European Geriatric Medicine 2010;1:112-21. [DOI: 10.1016/j.eurger.2010.01.010] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
316 Marlet J, Gaudy-Graffin C, Marc D, Boennec R, Goudeau A. Factors associated with influenza vaccination failure and severe disease in a French region in 2015. PLoS One 2018;13:e0195611. [PMID: 29664931 DOI: 10.1371/journal.pone.0195611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
317 Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, Gross FL, Steward-Clark E, Cao W, Jefferson S, Veguilla V, Gillis E, Meece J, Bai Y, Tatum H, Hancock K, Stevens J, Spencer S, Chen J, Gargiullo P, Braun E, Griffin MR, Sundaram M, Belongia EA, Shay DK, Katz JM, Sambhara S. Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses. Open Forum Infect Dis 2015;2:ofv052. [PMID: 26380344 DOI: 10.1093/ofid/ofv052] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
318 Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Dramé M, Roman F, Gillard P. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011;203:1054-62. [PMID: 21450995 DOI: 10.1093/infdis/jiq174] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
319 Barrett PN, Portsmouth D, Ehrlich HJ. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert Rev Vaccines 2013;12:395-413. [PMID: 23560920 DOI: 10.1586/erv.13.21] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
320 Otani N, Shima M, Ueda T, Ichiki K, Nakajima K, Takesue Y, Okuno T. Evaluation of influenza vaccine-immunogenicity in cell-mediated immunity. Cell Immunol 2016;310:165-9. [PMID: 27665371 DOI: 10.1016/j.cellimm.2016.09.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
321 Baras B, Stittelaar KJ, Kuiken T, Jacob V, Bernhard R, Giannini S, de Waal L, van Amerongen G, Simon JH, Osterhaus AD, Hanon E, Mossman SP. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 2011;29:2092-9. [DOI: 10.1016/j.vaccine.2010.12.128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
322 Dolfi DV, Mansfield KD, Kurupati RK, Kannan S, Doyle SA, Ertl HC, Schmader KE, Wherry EJ. Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans. PLoS One 2013;8:e77164. [PMID: 24155927 DOI: 10.1371/journal.pone.0077164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
323 Murray MA, Chotirmall SH. The Impact of Immunosenescence on Pulmonary Disease. Mediators Inflamm 2015;2015:692546. [PMID: 26199462 DOI: 10.1155/2015/692546] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
324 Lingblom CMD, Kowli S, Swaminathan N, Maecker HT, Lambert SL. Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults. J Transl Med 2018;16:153. [PMID: 29866115 DOI: 10.1186/s12967-018-1528-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
325 Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, Kroeze EJ, van den Brand JM, van Amerongen G, Simon JH, Hanon E, Mossman SP, Osterhaus AD. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets. Vaccine 2011;29:2120-6. [PMID: 21238573 DOI: 10.1016/j.vaccine.2010.12.125] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
326 Haq K, Fulop T, Tedder G, Gentleman B, Garneau H, Meneilly GS, Kleppinger A, Pawelec G, McElhaney JE. Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status. J Gerontol A Biol Sci Med Sci 2017;72:1163-70. [PMID: 27789617 DOI: 10.1093/gerona/glw216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
327 Lorenzo EC, Torrance BL, Keilich SR, Al-Naggar I, Harrison A, Xu M, Bartley JM, Haynes L. Senescence-induced changes in CD4 T cell differentiation can be alleviated by treatment with senolytics. Aging Cell 2022;21:e13525. [PMID: 34962049 DOI: 10.1111/acel.13525] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol 2015;386:151-80. [PMID: 25038938 DOI: 10.1007/82_2014_406] [Cited by in Crossref: 19] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
329 Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, von Lilienfeld-Toal M. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol 2022. [PMID: 35277694 DOI: 10.1038/s41571-022-00610-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
330 McMasters M, Blair BM, Lazarus HM, Alonso CD. Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation. Blood Rev 2021;47:100779. [PMID: 33223246 DOI: 10.1016/j.blre.2020.100779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
331 Huaman MC, Martin LB, Malkin E, Narum DL, Miller LH, Mahanty S, Long CA. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol 2008;180:1451-61. [PMID: 18209040 DOI: 10.4049/jimmunol.180.3.1451] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
332 van Els C, Mjaaland S, Næss L, Sarkadi J, Gonczol E, Korsholm KS, Hansen J, de Jonge J, Kersten G, Warner J, Semper A, Kruiswijk C, Oftung F. Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother 2014;10:1935-48. [PMID: 25424803 DOI: 10.4161/hv.28639] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
333 Smith LR, Wodal W, Crowe BA, Kerschbaum A, Bruehl P, Schwendinger MG, Savidis-Dacho H, Sullivan SM, Shlapobersky M, Hartikka J, Rolland A, Barrett PN, Kistner O. Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines. Hum Vaccin Immunother 2013;9:1333-45. [PMID: 23857272 DOI: 10.4161/hv.24209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
334 Salerno-Gonçalves R, Sztein MB. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol 2006;14:536-42. [PMID: 17055276 DOI: 10.1016/j.tim.2006.10.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
335 Farahtaj F, Gholami A, Khosravy MS, Gharibzadeh S, Niknam HM, Ghaemi A. Enhancement of immune responses by co-stimulation of TLR3 - TLR7 agonists as a potential therapeutics against rabies in mouse model. Microb Pathog 2021;157:104971. [PMID: 34029660 DOI: 10.1016/j.micpath.2021.104971] [Reference Citation Analysis]
336 Mcelhaney JE. Immunosenescence Modulation by Vaccination. In: Fulop T, Franceschi C, Hirokawa K, Pawelec G, editors. Handbook of Immunosenescence. Cham: Springer International Publishing; 2017. pp. 1-26. [DOI: 10.1007/978-3-319-64597-1_71-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
337 Nakaya HI, Pulendran B. Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS 2012;7:24-31. [PMID: 22156839 DOI: 10.1097/COH.0b013e32834dc37b] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
338 Xing Z, Cardona CJ. Preexisting immunity to pandemic (H1N1) 2009. Emerg Infect Dis 2009;15:1847-9. [PMID: 19891882 DOI: 10.3201/eid1511.090685] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
339 Wagar LE, Gentleman B, Pircher H, McElhaney JE, Watts TH. Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response. PLoS One 2011;6:e23698. [PMID: 21887299 DOI: 10.1371/journal.pone.0023698] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
340 Allen JC, Toapanta FR, Chen W, Tennant SM. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine 2020;38:8264-72. [PMID: 33229108 DOI: 10.1016/j.vaccine.2020.11.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
341 Hodgins B, Pillet S, Landry N, Ward BJ. Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge. Immun Ageing 2019;16:27. [PMID: 31700523 DOI: 10.1186/s12979-019-0167-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
342 Mahnke YD, Saqr A, Hazenfeld S, Brady RC, Roederer M, Subbramanian RA. Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses. Vaccine 2011;29:8606-14. [PMID: 21939709 DOI: 10.1016/j.vaccine.2011.09.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
343 Frasca D, Blomberg BB. B Cell-Specific Biomarkers for Optimal Antibody Responses to Influenza Vaccination and Molecular Pathways That Reduce B Cell Function with Aging. Crit Rev Immunol 2016;36:523-37. [PMID: 28845758 DOI: 10.1615/CritRevImmunol.2017020113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
344 Zhou X, Hopkins JW, Wang C, Brahmakshatriya V, Swain SL, Kuchel GA, Haynes L, McElhaney JE. IL-2 and IL-6 cooperate to enhance the generation of influenza-specific CD8 T cells responding to live influenza virus in aged mice and humans. Oncotarget 2016;7:39171-83. [PMID: 27322555 DOI: 10.18632/oncotarget.10047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
345 Samson SI, Leventhal PS, Salamand C, Meng Y, Seet BT, Landolfi V, Greenberg D, Hollingsworth R. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert Review of Vaccines 2019;18:295-308. [DOI: 10.1080/14760584.2019.1575734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
346 Effros RB. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine. 2007;25:599-604. [PMID: 17014937 DOI: 10.1016/j.vaccine.2006.08.032] [Cited by in Crossref: 113] [Cited by in F6Publishing: 100] [Article Influence: 7.1] [Reference Citation Analysis]
347 Mcelhaney J, Dutz J. Better Influenza Vaccines for Older People: What Will It Take? J INFECT DIS 2008;198:632-4. [DOI: 10.1086/590435] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
348 Pfleiderer M, Trouvin JH, Brasseur D, Gränstrom M, Shivji R, Mura M, Cavaleri M. Summary of knowledge gaps related to quality and efficacy of current influenza vaccines. Vaccine 2014;32:4586-91. [PMID: 24954696 DOI: 10.1016/j.vaccine.2014.05.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
349 Lee YN, Kim MC, Lee YT, Kim YJ, Kang SM. Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines. Immune Netw 2015;15:213-21. [PMID: 26557805 DOI: 10.4110/in.2015.15.5.213] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
350 Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated influenza vaccines. Vaccines. Elsevier; 2008. pp. 259-90. [DOI: 10.1016/b978-1-4160-3611-1.50019-2] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
351 Bechman K, Dey M, Yates M, Bukhari M, Winthrop K, Galloway JB. The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know. J Rheumatol 2021;48:1201-4. [PMID: 34074678 DOI: 10.3899/jrheum.210106] [Reference Citation Analysis]
352 Paich HA, Sheridan PA, Handy J, Karlsson EA, Schultz-Cherry S, Hudgens MG, Noah TL, Weir SS, Beck MA. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity (Silver Spring) 2013;21:2377-86. [PMID: 23512822 DOI: 10.1002/oby.20383] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 11.1] [Reference Citation Analysis]
353 Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Hum Vaccin Immunother 2013;9:1598-607. [PMID: 23846304 DOI: 10.4161/hv.25598] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
354 Park SA, Song ES, Cho YJ, Ahn BY, Ha SH, Seong BL, Lee KH, Lee NG. Immune responses of mice to influenza subunit vaccine in combination with CIA07 as an adjuvant. Microbiol Immunol 2007;51:1099-107. [PMID: 18037787 DOI: 10.1111/j.1348-0421.2007.tb04005.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
355 Ben-yedidia T. Progress towards a universal influenza vaccine. Future Virology 2011;6:237-48. [DOI: 10.2217/fvl.10.80] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
356 Chang CY, Lin CW, Chiang SK, Chen PL, Huang CY, Liu SJ, Chong P, Huang MH. Enzymatic stability and immunoregulatory efficacy of a synthetic indolicidin analogue with regular enantiomeric sequence. ACS Med Chem Lett 2013;4:522-6. [PMID: 24900703 DOI: 10.1021/ml400081f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
357 Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011;162:19-30. [PMID: 21963677 DOI: 10.1016/j.virusres.2011.09.022] [Cited by in Crossref: 199] [Cited by in F6Publishing: 179] [Article Influence: 18.1] [Reference Citation Analysis]
358 Fisher BM, Van Bockern J, Hart J, Lynch AM, Winn VD, Gibbs RS, Weinberg A. Pandemic influenza A H1N1 2009 infection versus vaccination: a cohort study comparing immune responses in pregnancy. PLoS One 2012;7:e33048. [PMID: 22457731 DOI: 10.1371/journal.pone.0033048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
359 Athale S, Banchereau R, Thompson-Snipes L, Wang Y, Palucka K, Pascual V, Banchereau J. Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets. Sci Transl Med 2017;9:eaaf9194. [PMID: 28330867 DOI: 10.1126/scitranslmed.aaf9194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
360 Staneková Z, Varečková E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010;7:351. [PMID: 21118546 DOI: 10.1186/1743-422X-7-351] [Cited by in Crossref: 97] [Cited by in F6Publishing: 49] [Article Influence: 8.1] [Reference Citation Analysis]
361 Booth JS, Goldberg E, Patil SA, Barnes RS, Greenwald BD, Sztein MB. Age-dependency of terminal ileum tissue resident memory T cell responsiveness profiles to S. Typhi following oral Ty21a immunization in humans. Immun Ageing 2021;18:19. [PMID: 33874975 DOI: 10.1186/s12979-021-00227-y] [Reference Citation Analysis]
362 Furuya Y. Return of inactivated whole-virus vaccine for superior efficacy. Immunol Cell Biol 2012;90:571-8. [PMID: 21844883 DOI: 10.1038/icb.2011.70] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
363 Barkhordarian A, Iyer N, Shapshak P, Somboonwit C, Sinnott J, Chiappelli F. Influenza 2009 pandemic: Cellular immunemediated surveillance modulated by TH17 & Tregs. Bioinformation 2011;6:39-40. [PMID: 21464844 DOI: 10.6026/97320630006039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
364 Guérin-El Khourouj V, Duchamp M, Krivine A, Pédron B, Ouachée-Chardin M, Yakouben K, Frémond ML, Baruchel A, Dalle JH, Sterkers G. Cellular and humoral immunity elicited by influenza vaccines in pediatric hematopoietic-stem cell transplantation. Hum Immunol 2012;73:884-90. [PMID: 22820626 DOI: 10.1016/j.humimm.2012.07.039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
365 Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, Sette A. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 2008;82:12241-51. [PMID: 18842709 DOI: 10.1128/JVI.01563-08] [Cited by in Crossref: 144] [Cited by in F6Publishing: 100] [Article Influence: 10.3] [Reference Citation Analysis]
366 Fan R, Huang X, Nian X, Ou Z, Zhou J, Zhang J, Zeng P, Zhao W, Deng J, Chen W, Chen S, Duan K, Chen Y, Li X, Zhang J, Yang X. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study. Hum Vaccin Immunother 2021;:1-9. [PMID: 34473607 DOI: 10.1080/21645515.2021.1967041] [Reference Citation Analysis]
367 Velasco-Medina AA, García-León ML, Velázquez-Sámano G, Wong-Chew RM. The cellular and humoral immune response to influenza vaccination is comparable in asthmatic and healthy subjects. Hum Vaccin Immunother 2021;17:98-105. [PMID: 32437230 DOI: 10.1080/21645515.2020.1759995] [Reference Citation Analysis]
368 Del Campo J, Bouley J, Chevandier M, Rousset C, Haller M, Indalecio A, Guyon-Gellin D, Le Vert A, Hill F, Djebali S, Leverrier Y, Marvel J, Combadière B, Nicolas F. OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza. Front Immunol 2021;12:678483. [PMID: 34177921 DOI: 10.3389/fimmu.2021.678483] [Reference Citation Analysis]
369 McElhaney JE. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging health 2008;4:603-13. [PMID: 20011611 DOI: 10.2217/1745509X.4.6.603] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
370 Fichera E, Felnerova D, Mischler R, Viret JF, Glueck R. New strategies to overcome the drawbacks of currently available flu vaccines. Adv Exp Med Biol 2009;655:243-52. [PMID: 20047044 DOI: 10.1007/978-1-4419-1132-2_15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
371 Michel JJ, Griffin P, Vallejo AN. Functionally Diverse NK-Like T Cells Are Effectors and Predictors of Successful Aging. Front Immunol 2016;7:530. [PMID: 27933066 DOI: 10.3389/fimmu.2016.00530] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
372 Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007;25:3066-3069. [PMID: 17275144 DOI: 10.1016/j.vaccine.2007.01.025] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 8.0] [Reference Citation Analysis]
373 Crosby CM, Matchett WE, Anguiano-Zarate SS, Parks CA, Weaver EA, Pease LR, Webby RJ, Barry MA. Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses. J Virol 2017;91:e00720-16. [PMID: 27807231 DOI: 10.1128/JVI.00720-16] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
374 Mombelli M, Kampouri E, Manuel O. Influenza in solid organ transplant recipients: epidemiology, management, and outcomes. Expert Review of Anti-infective Therapy 2020;18:103-12. [DOI: 10.1080/14787210.2020.1713098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
375 Merani S, Kuchel GA, Kleppinger A, McElhaney JE. Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol 2018;107:116-25. [PMID: 28958701 DOI: 10.1016/j.exger.2017.09.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
376 Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CGM, Bijl M. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology 2009;48:1294-9. [DOI: 10.1093/rheumatology/kep200] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
377 Alexander J, Bilsel P, del Guercio MF, Marinkovic-Petrovic A, Southwood S, Stewart S, Ishioka G, Kotturi MF, Botten J, Sidney J, Newman M, Sette A. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Hum Immunol 2010;71:468-74. [PMID: 20156506 DOI: 10.1016/j.humimm.2010.02.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
378 Andrew MK, Bowles SK, Pawelec G, Haynes L, Kuchel GA, McNeil SA, McElhaney JE. Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. Drugs Aging 2019;36:29-37. [PMID: 30411283 DOI: 10.1007/s40266-018-0597-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
379 Carter C, Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, Sarwar U, Larkin B, Bailer RT, Koup R, Chen GL, Patel SM, Winokur P, Belshe R, Dekker CL, Graham BS, Ledgerwood JE; VRC 703 study team. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS One 2019;14:e0222178. [PMID: 31532789 DOI: 10.1371/journal.pone.0222178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
380 Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol 2013;4:171. [PMID: 23825474 DOI: 10.3389/fimmu.2013.00171] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
381 McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 2009;21:418-24. [PMID: 19570667 DOI: 10.1016/j.coi.2009.05.023] [Cited by in Crossref: 216] [Cited by in F6Publishing: 196] [Article Influence: 16.6] [Reference Citation Analysis]
382 Coughlan L, Lambe T. Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. Vaccines (Basel). 2015;3:293-319. [PMID: 26343189 DOI: 10.3390/vaccines3020293] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
383 van Assen S, Holvast A, Telgt DS, Benne CA, de Haan A, Westra J, Kallenberg CG, Bijl M. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin Immunol 2010;136:228-35. [PMID: 20421178 DOI: 10.1016/j.clim.2010.03.430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
384 Duraisingham SS, Rouphael N, Cavanagh MM, Nakaya HI, Goronzy JJ, Pulendran B. Systems biology of vaccination in the elderly. Curr Top Microbiol Immunol 2013;363:117-42. [PMID: 22903566 DOI: 10.1007/82_2012_250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
385 Wong PT, Goff PH, Sun RJ, Ruge MJ, Ermler ME, Sebring A, O'Konek JJ, Landers JJ, Janczak KW, Sun W, Baker JR Jr. Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus. Mol Pharm 2021;18:679-98. [PMID: 32491861 DOI: 10.1021/acs.molpharmaceut.0c00315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
386 Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, Montomoli E, Del Giudice G, Rappuoli R, O’hagan DT. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008;26:552-61. [DOI: 10.1016/j.vaccine.2007.11.054] [Cited by in Crossref: 134] [Cited by in F6Publishing: 122] [Article Influence: 9.6] [Reference Citation Analysis]
387 Gianchecchi E, Torelli A, Montomoli E. The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity. Hum Vaccin Immunother 2019;15:1021-30. [PMID: 30614754 DOI: 10.1080/21645515.2019.1565269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
388 Sanei F, Wilkinson T. Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness. Ther Adv Respir Dis 2016;10:349-67. [PMID: 27193567 DOI: 10.1177/1753465816646050] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
389 Mcelhaney JE. Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Review of Vaccines 2014;8:593-606. [DOI: 10.1586/erv.09.12] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
390 Jones S, Evans K, Mcelwaine-johnn H, Sharpe M, Oxford J, Lambkin-williams R, Mant T, Nolan A, Zambon M, Ellis J, Beadle J, Loudon PT. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009;27:2506-12. [DOI: 10.1016/j.vaccine.2009.02.061] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 8.5] [Reference Citation Analysis]
391 Jones SC, Clise-Dwyer K, Huston G, Dibble J, Eaton S, Haynes L, Swain SL. Impact of post-thymic cellular longevity on the development of age-associated CD4+ T cell defects. J Immunol 2008;180:4465-75. [PMID: 18354168 DOI: 10.4049/jimmunol.180.7.4465] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
392 Hagan T, Nakaya HI, Subramaniam S, Pulendran B. Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine 2015;33:5294-301. [PMID: 25858860 DOI: 10.1016/j.vaccine.2015.03.072] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 10.7] [Reference Citation Analysis]